Many pharmaceutical companies are underestimating how difficult achieving ePI readiness will become once implementation deadlines move closer. What initially appears to be a straightforward compliance initiative often turns into a complex transformation involving regulatory workflows, structured content authoring based on HL7 FHIR standards, multilingual labeling, IT system integration, governance, and lifecycle management. Without a realistic implementation roadmap and cost plan, organizations risk delayed submissions, overwhelmed internal teams, and rapidly increasing remediation costs.
The biggest issue is that many companies underestimate the true scope of implementation until the project is already underway. Without a clear strategy for ePI readiness, organizations risk delayed submissions, duplicated manual work, process inefficiencies, and expensive corrective actions later in the process. The EMA ePI Roadmap published in 2024 [2] confirms that implementation is already underway across member states, making early preparation a competitive necessity, not just a compliance formality.
That is why pharmaceutical companies increasingly seek experienced partners who can realistically assess implementation timelines and cost drivers while providing a practical roadmap toward full ePI readiness. At Billev Pharma East, we help organizations reduce implementation risk, optimize timelines, and build scalable ePI strategies that support long-term regulatory efficiency. Instead of reactive fixes and fragmented execution, we help companies establish structured, sustainable, and cost-effective readiness programs before regulatory pressure intensifies further.
What must companies do to achieve ePI readiness?
Achieving full ePI readiness requires much more than converting existing PDFs into digital files or simply selecting an ePI vendor. Pharmaceutical companies must prepare for a long-term transformation that affects regulatory processes, content governance, labeling workflows, IT infrastructure, and lifecycle management. This is why building a realistic implementation roadmap with clear cost estimates is essential from the very beginning. Companies that approach ePI as a simple compliance task often face delayed implementation, budget overruns, and significant disruption later in the process. Based on typical industry patterns, a full ePI readiness programme for a mid-sized pharmaceutical company spans 18 to 24 months and involves sequential phases: gap assessment, governance design, vendor selection, pilot implementation, and full rollout. Understanding this scope early is what separates successful implementations from costly ones.
The first step is conducting a comprehensive gap assessment. Organizations need to evaluate the maturity of their current labeling processes, document structures, multilingual workflows, system capabilities, and overall readiness for collaboration with an ePI vendor. Many companies discover that their existing product information is not structured in a way that supports future ePI requirements, especially as EMA continues developing standardized FHIR-based electronic formats [1] and interoperability expectations across member states.
Next, companies must establish a clear implementation roadmap that defines timelines, responsibilities, governance models, resource allocation, technology requirements, and vendor coordination strategies. Successful ePI readiness requires clear ownership across Regulatory Affairs, IT, labeling, quality teams, and external ePI vendor activities to prevent fragmented execution and delayed implementation. Without proper alignment, projects quickly become difficult to manage.
Organizations must also prepare for ongoing lifecycle management, because ePI is not a one-time implementation project. Once electronic product information becomes part of regulatory processes, every future variation, update, and submission must follow structured digital workflows. This significantly increases the importance of scalable governance strategies and choosing an ePI vendor capable of supporting long-term regulatory and technical requirements.
Most importantly, companies should begin preparation early. Early planning reduces implementation risk, improves organizational efficiency, and results in more accurate cost planning and timeline management — helping organizations avoid expensive remediation efforts and unnecessary delays later in the process.
Common mistakes companies make during ePI readiness preparation
One of the most common mistakes companies make is underestimating how complex ePI readiness actually becomes once implementation begins. Many organizations approach ePI as a simple compliance exercise instead of a long-term transformation affecting regulatory workflows, structured content, governance, multilingual labeling, and lifecycle management. As a result, initial implementation timelines and budgets are often unrealistic, leading to delayed submissions, resource pressure, and rising remediation costs later in the process. Another major issue is relying on disconnected systems and manual workflows that were never designed to support structured electronic product information. Without experienced experts involved early, companies frequently struggle with unclear ownership, inconsistent execution, and overwhelmed internal teams. Organizations that prepare proactively with realistic planning and expert guidance are significantly better positioned to achieve sustainable ePI readiness while avoiding costly delays and operational inefficiencies.
How Billev Pharma East helps companies achieve ePI readiness faster
For many pharmaceutical companies, the real challenge is not understanding the direction of ePI regulation or evolving ePI requirements, it is finding a partner capable of turning complexity into a clear, executable strategy. This is where Billev Pharma East becomes essential. We help organizations build realistic implementation roadmaps and cost frameworks through a practical, scalable, and execution-focused approach designed specifically to support long-term ePI readiness within complex pharmaceutical environments.
What truly differentiates Billev Pharma East is our team of experienced experts who combine deep regulatory knowledge with hands-on implementation expertise. Our specialists understand how ePI readiness impacts every stage of the product information lifecycle, from structured content and labeling workflows to governance, submission readiness, multilingual coordination, and long-term lifecycle management. Because of this, we do not deliver generic recommendations — we provide realistic solutions that help companies prepare for increasingly complex ePI requirements within highly regulated pharmaceutical environments.
Many pharmaceutical companies simply do not have the internal capacity to manage ePI transformation efficiently while maintaining daily regulatory activities. Without experienced experts leading the process, implementation timelines often expand, ownership becomes unclear, and internal teams become overloaded. At Billev Pharma East, we help companies reduce this internal resource pressure by bringing structure, expertise, and execution support directly into the implementation process.
Our experts actively support implementation planning, governance setup, workflow optimization, and regulatory coordination to ensure projects move forward efficiently without unnecessary delays or costly remediation work. Each engagement begins with a structured ePI Readiness Assessment that produces a written gap report, a phased implementation roadmap, and an indicative cost framework — giving leadership a clear basis for decision-making before any vendor investment is made. This allows pharmaceutical companies to move forward with confidence instead of constantly reacting to regulatory pressure, evolving ePI requirements, and execution bottlenecks.
As EMA implementation timelines continue progressing, companies that act early with the right partner will gain a major advantage. At Billev Pharma East, we help pharmaceutical organizations transform ePI complexity into a manageable, efficient, and sustainable ePI readiness strategy — one that reduces risk, controls costs, and prepares teams for the future of digital regulatory operations.
What is important when preparing ePI project timelines and cost estimates?
Building an accurate ePI project timeline and realistic cost plan requires far more than estimating implementation dates and assigning budgets. The most successful pharmaceutical companies approach ePI readiness as a long-term operational transformation that impacts regulatory processes, structured content management, governance, labeling workflows, multilingual coordination, and future lifecycle maintenance. Companies that underestimate these areas often experience delayed timelines, rising implementation costs, and significant operational inefficiencies later in the project.
One of the most important factors is early assessment of internal process maturity. Organizations must understand whether their current labeling systems, document structures, and regulatory workflows are capable of supporting future electronic product information requirements. In many cases, existing processes were not designed for structured digital content, which creates additional remediation work during implementation.
Another critical area is cross-functional alignment. Successful ePI readiness depends on strong collaboration between Regulatory Affairs, IT, Quality, labeling, and operational teams. Without clear ownership and governance, projects quickly become fragmented, leading to duplicated work, communication gaps, and unrealistic implementation timelines and budget overruns.
Companies must also prepare for long-term scalability. ePI is not a one-time compliance project — it changes how product information is created, maintained, updated, and submitted throughout the entire product lifecycle. This means implementation strategies must support future variations, multilingual updates, structured data requirements, and evolving regulatory expectations.
Most importantly, organizations should focus on practical execution rather than theoretical planning. Early preparation, realistic timelines, and experienced guidance significantly reduce implementation risk and help companies achieve sustainable ePI readiness with lower long-term operational costs.
Build a sustainable strategy for ePI readiness
As regulatory expectations continue evolving, pharmaceutical companies can no longer afford reactive approaches to ePI implementation. Building an accurate ePI implementation timeline and achieving long-term ePI readiness requires strategic planning, implementation expertise, and a partner who understands the real complexity behind digital regulatory transformation. Companies that start preparing early will be significantly better positioned to reduce regulatory risk, control long-term costs, and maintain efficient submission processes as ePI requirements continue expanding.
At Billev Pharma East, our experts help pharmaceutical organizations move beyond uncertainty by delivering practical, scalable, and execution-focused ePI strategies tailored to complex regulatory environments. We combine deep industry expertise with hands-on implementation support to help companies accelerate readiness, strengthen governance, and avoid costly delays caused by poor planning or fragmented execution.
For organizations looking to achieve sustainable ePI readiness with a clear implementation plan and realistic cost framework, Billev Pharma East provides the expertise, structured assessment methodology, and strategic guidance needed to reduce regulatory risk and accelerate execution. Contact us to schedule an initial ePI readiness consultation and receive a tailored gap assessment for your organization.
Read also:
- Recommended tools for structured product labeling updates: why ePI consultancy matters before choosing an electronic product information vendor
- ePI requirements: what pharma companies must do now to stay compliant under the new EU legislation
Sources: 1 – European Medicines Agency. (n.d.). Electronic product information (ePI), 2 – European Medicines Agency. (2024). Electronic product information (ePI) roadmap.
Image credits:
In-article images: Freepik
In-article images: Freepik
Hero image: Freepik